A Phase II Study of Combination Chemotherapy with Gemcitabine, 5-fluorouracil, and Cisplatin for Advanced Pancreatic Cancer.
- Author:
Sang Bong CHOI
1
;
Hwal Youn LEE
;
Young Jin YUH
;
Sung Rok KIM
Author Information
1. Department of Internal Medicine, Inje University Collage of Medicine, Sanggye Paik Hospital, Seoul, Korea. sungrkim@sanggyepaik.or.kr
- Publication Type:Original Article ; Clinical Trial, Phase II ; English Abstract
- Keywords:
Pancreatic cancer;
Gemcitabine;
5-fluorouracil;
Cisplatin
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Cisplatin/administration & dosage;
Deoxycytidine/administration & dosage/analogs & derivatives;
Female;
Fluorouracil/administration & dosage;
Humans;
Male;
Middle Aged;
Pancreatic Neoplasms/*drug therapy/mortality;
Survival Rate
- From:The Korean Journal of Gastroenterology
2005;45(5):348-353
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Gemcitabine has been the standard regimen for advanced pancreatic cancer, but the effect on the response rate and survival is still disappointing, leading to many trials of combination chemotherapy. 5-FU and cisplatin were combined with gemcitabine in this trial, as they are synergistic with gemcitabine and each other as well. This study was aimed to assess the effectiveness and safety of combination chemotherapy with gemcitabine, 5-FU, and cisplatin for advanced pancreatic cancer. METHODS: Patients with advanced pancreatic cancer were entered into this study. Gemcitabine at a dose of 800 mg/m2 on day 1 and 8, 5-FU 1,000 mg/m2/day from day 1 to 3 for 72 hours, and cisplatin 60 mg/m2 on day 2, 24 hours after the start of gemcitabine were administered every 3 weeks. RESULTS: From December 2001 to January 2004, twenty patients were enrolled in this study. Among 17 of these patients assessable, 3 patients had a partial remission with the response rate of 17.7% (95% confidence interval, 6.2-41.0%). The median time to disease progression was 230 days and median duration of survival was 322 days. Among total of 91 cycles, leukopenia, neutropenia, and thrombocytopenia of grade 3 or 4 occurred in 12 cycles (13.2%), 12 cycles (13.2%), and 23 cycles (24.4%), respectively. Grade 3 or 4 mucositis developed at 2 cycles (2.2%), and nausea and vomiting were encountered in 3 cycles (3.3%). CONCLUSIONS: Combination chemotherapy with gemcitabine, 5-FU, and cisplatin for advanced pancreatic cancer is active and well-tolerated, warranting a phase III study.
